Significantly lower expression of Plk2 has been observed in a wide range of B-cell neoplasms due to CpG methylation that causes transcriptional silencing of Plk2, supporting the role of Plk2 as a tumor suppressor in hematopoietic diseases [13]. This evidence concerns the gene PLK2 and neoplasm.